相关实验视频

Updated: May 20, 2025

Modeling Alcohol Consumption in Rodents Using Two-Bottle Choice Home Cage Drinking and Microstructural Analysis

Modeling Alcohol Consumption in Rodents Using Two-Bottle Choice Home Cage Drinking and Microstructural Analysis

Published on: November 8, 2024

血甲基乙醇测量表明GLP-1受体刺激导致酒精消耗延迟下降

Mathias E Jensen¹, Mette K Klausen¹, Marianne L Bergmann²

¹Psychiatric Centre Copenhagen, Frederiksberg, University of Copenhagen, Copenhagen, Denmark.

Alcohol, clinical & experimental research

|March 24, 2025

概括

作为GLP-1受体激动剂的exenatide在26周之前显著降低了酒精消费,这些人患有酒精使用障碍和肥胖症. 这表明酒精使用障碍 (AUD) 和肥胖症的治疗效果延迟.

科学领域:

药理学和成医学药理学和成医学
代谢和内分泌疾病代谢和内分泌疾病

背景情况:

针对酒精使用障碍 (AUD) 和肥胖症的葡萄糖类1 (GLP-1) 受体激动剂 (GLP-1RA) 的研究.
一个随机的安慰剂对照试验的二次分析,重点是AUD患者的伴随性肥胖症.

研究的目的:

评估exenatide与安慰剂对AUD肥胖患者酒精消费的影响.
使用酸乙醇 (PEth) 生物标志物测量酒精消耗.

主要方法:

包括30名AUD患者 (平均年龄53岁,BMI≥30kg/m2).
在基线和4周,12周,20周和26周收集了PEth的血液样本.
通过对时间和治疗效应进行基线调整的线性混合模型分析PEth水平.

主要成果:

在第26周 (p=0.03) 观察到显著的治疗时间相互作用.
在第26周,与安慰剂相比,exenatide组显示PEth水平显著降低 (-0.9μmol/L).
在早期的时间点中,在组之间没有发现PEth水平的显著差异.

结论:

埃克萨纳提德在AUD和肥胖症患者中对酒精消费有延迟但显著的影响.
这些发现支持对GLP-1RA进行进一步的研究,用于管理伴随性AUD和肥胖症.
目前正在进行的临床试验 (NCT05895643) 将提供进一步的见解.

关键词:

作为GLP-1受体激活剂.第五个是Peth.酒精生物标志物酒精生物标志物酒精使用障碍饮酒障碍酸乙醇酸乙醇的使用方法

更多相关视频

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

A Simple Way to Measure Alterations in Reward-seeking Behavior Using Drosophila melanogaster

A Simple Way to Measure Alterations in Reward-seeking Behavior Using Drosophila melanogaster

Published on: December 15, 2016

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...